Literature DB >> 35029746

[Avoiding mistakes in anti-VEGF intravitreal injection therapy].

Carsten Framme1, Bernd Junker2, Nicolas Feltgen3, Hans Hoerauf3, Nina-Antonia Striebe3, Joachim Wachtlin4,5, Ingo Volkmann2.   

Abstract

Intravitreal injection (IVI) of drugs for treatment of various macular diseases is now one of the most frequently performed surgical procedures worldwide. As mostly chronic diseases are treated, the indications for treatment often mean a continuous treatment over years with a corresponding effort regarding spatial, personnel and financial resources. The diagnosis and indications for treatment are nowadays mainly made by spectral domain optical coherence tomography (SD-OCT). The ability to clinically assess and evaluate a fluorescence angiography is less practiced, although these are still a component of the indications for intravitreal injections. Therefore, it can happen that despite all diligence patients may receive anti-vascular endothelial growth factor (VEGF) treatment, sometimes permanently, based on a misinterpretation of the macular diagnosis or disease activity and these indications, once made, are rarely questioned or retracted. Therefore, the aim of this manuscript is to point out possible and typical misinterpretations in the indications or continuation of IVI treatment with anti-VEGF by means of case studies and to sensitize for differential diagnoses.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Age-related macular degeneration; Central serous chorioretinopathy; Intravitreal injections; Macular telangiectasis; Retinal macroaneurysm

Mesh:

Substances:

Year:  2022        PMID: 35029746     DOI: 10.1007/s00347-021-01553-8

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  38 in total

1.  Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.

Authors:  Jeffrey S Heier; Peter A Campochiaro; Linda Yau; Zhengrong Li; Namrata Saroj; Roman G Rubio; Phillip Lai
Journal:  Ophthalmology       Date:  2012-02-01       Impact factor: 12.079

2.  Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study.

Authors:  Peter A Campochiaro; Raafay Sophie; Joel Pearlman; David M Brown; David S Boyer; Jeffrey S Heier; Dennis M Marcus; Leonard Feiner; Arun Patel
Journal:  Ophthalmology       Date:  2013-10-07       Impact factor: 12.079

3.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.

Authors:  Jeffrey S Heier; W Lloyd Clark; David S Boyer; David M Brown; Robert Vitti; Alyson J Berliner; Husain Kazmi; Yu Ma; Brigitte Stemper; Oliver Zeitz; Rupert Sandbrink; Julia A Haller
Journal:  Ophthalmology       Date:  2014-03-27       Impact factor: 12.079

5.  Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.

Authors:  David M Brown; Peter A Campochiaro; Robert B Bhisitkul; Allen C Ho; Sarah Gray; Namrata Saroj; Anthony P Adamis; Roman G Rubio; Wendy Yee Murahashi
Journal:  Ophthalmology       Date:  2011-08       Impact factor: 12.079

6.  The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

Authors:  Paul Mitchell; Francesco Bandello; Ursula Schmidt-Erfurth; Gabriele E Lang; Pascale Massin; Reinier O Schlingemann; Florian Sutter; Christian Simader; Gabriela Burian; Ortrud Gerstner; Andreas Weichselberger
Journal:  Ophthalmology       Date:  2011-04       Impact factor: 12.079

7.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

Authors:  Quan Dong Nguyen; David M Brown; Dennis M Marcus; David S Boyer; Sunil Patel; Leonard Feiner; Andrea Gibson; Judy Sy; Amy Chen Rundle; J Jill Hopkins; Roman G Rubio; Jason S Ehrlich
Journal:  Ophthalmology       Date:  2012-02-11       Impact factor: 12.079

8.  Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study.

Authors:  Pascale Massin; Francesco Bandello; Justus G Garweg; Lutz L Hansen; Simon P Harding; Michael Larsen; Paul Mitchell; Dianne Sharp; U E K Wolf-Schnurrbusch; Margarita Gekkieva; Andreas Weichselberger; Sebastian Wolf
Journal:  Diabetes Care       Date:  2010-11       Impact factor: 19.112

9.  Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.

Authors:  John A Wells; Adam R Glassman; Allison R Ayala; Lee M Jampol; Neil M Bressler; Susan B Bressler; Alexander J Brucker; Frederick L Ferris; G Robert Hampton; Chirag Jhaveri; Michele Melia; Roy W Beck
Journal:  Ophthalmology       Date:  2016-02-27       Impact factor: 12.079

10.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Authors:  Jeffrey S Heier; David M Brown; Victor Chong; Jean-Francois Korobelnik; Peter K Kaiser; Quan Dong Nguyen; Bernd Kirchhof; Allen Ho; Yuichiro Ogura; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Georg Groetzbach; Bernd Sommerauer; Rupert Sandbrink; Christian Simader; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2012-10-17       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.